Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Détails

ID Serval
serval:BIB_09CB11B7B0DA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Périodique
British journal of pharmacology
Auteur⸱e⸱s
Berger N.A., Besson V.C., Boulares A.H., Bürkle A., Chiarugi A., Clark R.S., Curtin N.J., Cuzzocrea S., Dawson T.M., Dawson V.L., Haskó G., Liaudet L., Moroni F., Pacher P., Radermacher P., Salzman A.L., Snyder S.H., Soriano F.G., Strosznajder R.P., Sümegi B., Swanson R.A., Szabo C.
ISSN
1476-5381 (Electronic)
ISSN-L
0007-1188
Statut éditorial
Publié
Date de publication
01/2018
Peer-reviewed
Oui
Volume
175
Numéro
2
Pages
192-222
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

Pubmed
Web of science
Création de la notice
28/02/2017 19:17
Dernière modification de la notice
20/08/2019 12:31
Données d'usage